Your browser doesn't support javascript.
loading
Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.
Ebeling, Peter; Bach, P; Sorg, U; Schneider, A; Trarbach, T; Dilloo, D; Hanenberg, H; Niesert, S; Seeber, S; Moritz, T; Flasshove, M.
Afiliación
  • Ebeling P; Department of Internal Medicine (Cancer Research), University of Duisburg-Essen Medical School, Hufelandstrasse 55, 45122 Essen, Germany. peter.ebeling@uni-essen.de
J Cancer Res Clin Oncol ; 133(3): 199-209, 2007 Mar.
Article en En | MEDLINE | ID: mdl-17053889
ABSTRACT

PURPOSE:

Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model.

METHODS:

An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only.

RESULT:

While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 +/- 2.3 vs. 22.1 +/- 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 +/- 0.9 vs. 11.6 +/- 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 +/- 1.7 vs. 36.5 +/- 9.4%) and EGFP expression in these cells (0 +/- 0 vs. 11.3 +/- 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFbeta11-EGFP, high transduction rates for CD45+ (41.0 +/- 5.3%) and CD34+ (38.5 +/- 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 +/- 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 +/- 2.0%), myeloid (36.5 +/- 3.5%) and CD34+ cells (10.1 +/- 1.5%).

CONCLUSION:

Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFbeta11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Hematopoyéticas / Inmunodeficiencia Combinada Grave / Técnicas de Transferencia de Gen / Trasplante de Células Madre de Sangre del Cordón Umbilical / Proteínas Fluorescentes Verdes / Supervivencia de Injerto Tipo de estudio: Evaluation_studies / Guideline Límite: Animals / Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2007 Tipo del documento: Article País de afiliación: Alemania
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Células Madre Hematopoyéticas / Inmunodeficiencia Combinada Grave / Técnicas de Transferencia de Gen / Trasplante de Células Madre de Sangre del Cordón Umbilical / Proteínas Fluorescentes Verdes / Supervivencia de Injerto Tipo de estudio: Evaluation_studies / Guideline Límite: Animals / Humans Idioma: En Revista: J Cancer Res Clin Oncol Año: 2007 Tipo del documento: Article País de afiliación: Alemania